CSTL
Castle Biosciences, Inc.
CSTL's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CSTL overall, supported by stronger fundamentals and lower modeled downside.
CSTL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CSTL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CSTL PE Valuation
CSTL has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CSTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CSTL's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CSTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.75 | -$0.30 |
| Q2 2026 | -$0.64 | -$0.29 |
| Q1 2026 | -$0.42 | -$0.23 |
| Q4 2025 | -$0.83 | -234% |
| Q3 2025 | -$0.45 | -305% |
| Q2 2025 | -$0.35 | -$0.23 |
| Q1 2025 | -$0.19 | +$0.94 |
| Q4 2024 | $0.62 | +$2.76 |
CSTL is still losing money, but far less than before: $0.75 per share over the past year, against $3.35 at its worst in mid-2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CSTL on earnings quality, reporting a profit while its opponent remains loss making.
CSTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.9M | +24% |
| Q2 2026 | $103.5M | +20% |
| Q1 2026 | $83.7M | -4.9% |
| Q4 2025 | $87M | +0.8% |
| Q3 2025 | $83M | -3.2% |
| Q2 2025 | $86.2M | -0.9% |
| Q1 2025 | $88M | +21% |
| Q4 2024 | $86.3M | +31% |
CSTL's revenue is growing: $103M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.6% | +5.5 points |
| Q2 2026 | -3% | +2 points |
| Q1 2026 | -22% | +9.7 points |
| Q4 2025 | -4.4% | -9.1 points |
| Q3 2025 | -8.2% | -14 points |
| Q2 2025 | -4.9% | -11 points |
| Q1 2025 | -32% | -24 points |
| Q4 2024 | 4.7% | +13 points |
CSTL's operating margin was −2.6% last quarter, up 5.5 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CSTL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CSTL on profitability, with a higher operating margin.
CSTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.2M | +57% |
| Q2 2026 | $6.6M | -43% |
| Q1 2026 | -$34.6M | -$23.8M |
| Q4 2025 | $19.7M | +18% |
| Q3 2025 | $7.8M | -54% |
| Q2 2025 | $11.6M | -38% |
| Q1 2025 | -$10.8M | +$5.2M |
| Q4 2024 | $16.8M | +14% |
CSTL still generates free cash flow, though less than at its 2025 peak: $4M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CSTL on cash flow, with more consistent year-over-year improvement.
CSTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +234K shares |
| 1 year | +5.4% | +1.6M shares |
| 3 years | +14% | +3.8M shares |
| 5 years | +21% | +5.3M shares |
| Available history | +64% | +11.9M shares |
CSTL has 31M diluted shares, up 5.4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CSTL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CSTL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
| Q2 2025 | -3.7x | Net Cash |
| Q1 2025 | -2.8x | Net Cash |
| Q4 2024 | -4.5x | Net Cash |
| Q3 2024 | -6.8x | Net Cash |
| Q2 2020 | -19.8x | Net Cash |
| Q1 2020 | -8.1x | Net Cash |
| Q4 2019 | -9.6x | Net Cash |
CSTL has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CSTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 63.5 | Neutral |
CSTL's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CSTL PE vs Healthcare Sector
| Metric | CSTL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSTL has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CSTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.4 | 0.3% above |
| 20 week MA | $31.5 | 9.6% above |
| 50 week MA | $30.0 | 15% above |
| 100 week MA | $26.4 | 31% above |
| 200 week MA | $24.4 | 41% above |
CSTL is in an uptrend: it's above all five of its weekly moving averages, and 41% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CSTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.0 | $71.3 | +110% |
| 2021 | $71.3 | $42.6 | -40% |
| 2022 | $42.6 | $23.2 | -45% |
| 2023 | $23.2 | $21.6 | -7.1% |
| 2024 | $21.6 | $26.8 | +24% |
| 2025 | $26.8 | $39.4 | +47% |
| 2026 YTD | $39.4 | $34.5 | -12% |
CSTL's yearly returns have swung widely, from +110% in 2020 to −45% in 2022. It's down 12% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CSTL on returns for 2026, with the stronger performance.